Effects of continuous medroxyprogesterone acetate on lipoprotein metabolism in postmenopausal women receiving estrogen

Maturitas

Volumn 25, Issue 1, 1996, Pages 35-44

  Wakatsuki, Akihiko ^a   Sagara, Yusuke ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Conjugated equine estrogen; Lipoprotein metabolism; Medroxyprogesterone acetate; Postmenopausal women

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPOPROTEIN METABOLISM; LIVER METABOLISM; MAJOR CLINICAL STUDY; POSTMENOPAUSE;

EQUIDAE;

EID: 0030219902     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(96)01044-4     Document Type: Article

References (39)

1. [1] Castelli W. Epidemiology of coronary heart diseases: The Framingham study. Am J Med 1984; 76: 4-12.
2. [2] Kannel WB. Metabolic risk factors for coronary artery disease in women: prospective from the Framingham study. Am Heart J 1987; 114: 413-419.
3. [3] Ettinger WH. Lipid levels and risk of atherosclerotic coronary heart disease in the old person. Med Clin North Am 1989; 73: 1525-1530.
4. [4] Wakatsuki A, Sagara Y. Lipoprotein metabolism in postmenopausal and oophorectomized women. Obstet Gynecol 1995; 85: 523-528.
5. [5] Area M, Vega GL, Grundy SM. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin, JAMA 1994; 271: 453-459.
6. [6] Windler E, Kovanen PT, Chao YS et al. The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem 1980; 255: 10464-10471.
7. [7] Ma PT, Yamamoto T, Goldstein JT, Brown MS. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha ethinyl estradiol. Proc Natl Acad Sci USA 1986; 83: 792-796.
8. [8] Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. Effects of estrogen on low density lipoprotein metabolism in males: short term and long term studies during hormonal treatment of prostatic carcinoma. J Clin Invest 1989; 84; 802-810.
9. [9] Tikkanen MJ, Kuusi T, Vartianen E, Nikkila A. Treatment of post-menopausal hypercholesterolemia with estradiol. Acta Obstet Gynecol Scand (Suppl) 1979; 88: 83-88.
10. [10] Colvin PL, Auerbach BJ, Case LD et al. A dose-response relationship between sex steroid hormone induced changes in hepatic triglyceride lipase and high density lipoprotein cholesterol in postmenopausal women. Metabolism 1991; 40: 1052-1056.
11. [11] Gordon J, Reagan JW, Finkle WD, Ziel HK: Estrogen and endometrial carcinoma: An independent pathology review supporting original risk estimate. N Engl J Med 1977; 297: 570-571.
12. [12] Antunes CM, Stolley PD, Rosenghein NB et al. Endometrial cancer and estrogen use: report of a large case-control study. N Eng J Med 1979; 300: 9-13.
13. [13] Gambrell RD, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progesterone challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980; 55: 732-738.
14. [14] Whitehead MI, Townsend PT, Pryse-Davies J et al. Actions of progestins on the morphology and biochemistry of the endometrium of postmenopausal women receiving low-dose estrogen therapy. Am J Obstet Gynecol 1982; 142: 791-795.
15. [15] Tikkanen M, Nikkila E. Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 1987; 113: 562-567.
16. [16] Kuusi T, Nikkila A, Tikkanen M et al. Effects of two progestins with different androgenic properties on hepatic endothelial lipase and high density lipoprotein. Atherosclerosis 1985; 54: 251-262.
17. [17] Lobo RA. Clinical Review 27, Effects of hormone replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925-930.
18. [18] Weinstein L, Bewtra CB, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopause patient. Am J Obstet Gynecol 1990; 162: 1534-1542.
19. [19] Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 151: 746-750.
20. 2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388.
21. [21] Allain CC, Poon LS. Chan CG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-475.
22. [22] Ikeda T, Shibuya Y, Senda U et al. Automated immunoturbidimetric analysis of six plasma apolipoproteins: correlation with radical immunodiffusion assays. J Clin Lab Anal 1991; 5: 90-95.
23. [23] Wright K, Robinson H, Collins DC, Preedy JRK. Investigation of a radioimmunoassay for plasma estrone and estradiol-17β in males and non-pregnant females. Comparison with an independent method. J Clin Endocr 1973; 36: 165-173.
24. [24] Baginsky ML, Brown WV. A new method for the measurement of lipoprotein lipase in postheparin plasma using sodium dodecyl sulfate for the inactivation of hepatic triglyceride lipase. J Lipid Res 1979; 20: 548-556.
25. [25] Dole VP. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Invest 1956; 35: 150-154.
26. [26] Shimizu S, Yasui K, Tani Y, Yamada H. Acyl-CoA oxidase from candida tropicalis. Biochem Biophys Res Commun 1979; 91: 108-113.
27. [27] Nagasaki T, Akanuma Y. A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin Chim Acta 1977; 75: 371-375.
28. [28] Anonymous. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
29. [29] Khokha R, Huff MW, Wolfe BM. Divergent effects of 17 d-norgestrel on the metabolism of rat very low density and low density lipoprotein B. J Lipid Res 1986; 27: 699-705.
30. [30] Carlson LA, Bottiger LE, Ahfeldt PE. Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979; 206: 351-360.
31. [31] Miller KW, Lane MD. Estradiol-induced alteration of very-low density lipoprotein assembly. J Biol Chem 1984; 259: 15277-15286.
32. [32] Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204.
33. [33] Fletcher CD, Farish E, Dagen MM, Hart DM. Short-term changes in lipoprotein and apoproteins during cyclical oestrogen-progestogen replacement therapy. Maturitas 1991; 14: 33-42.
34. [34] Kim H, Kalkhoff RK. Sex steroid influence on triglyceride metabolism. J Clin Invest 1975; 56: 888-896.
35. [35] Kenagy R, Weinstein I, Heimberg M. The effects of 17 beta-estradiol and progesterone on the metabolism of free fatt acid by perfused livers from normal female and ovariectomized rats. Endocrinology 1981; 108: 1613-1621.
36. [36] Anonymous. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
37. [37] Colvin PL, Auerbacb BJ, Case LD, Hazzard WR, Applebaum-Bowden D. A dose relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism 1991; 40: 1052-1056.
38. [38] Applebaum-Bowden D, McLean P, Steinmetz A et al. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 1989; 30: 1895-1906.
39. [39] Basdevant A, Lignieres B, Simon P et al. Hepatic lipase activity during oral and parenteral 17 β-estradiol replacement therapy: high density lipoprotein increase may not be antiatherogenic. Fertil Steril 1991; 55: 1112-1117.